Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab biomarker study in perianal fistulizing Crohn's disease
NL-OMON42625Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of vedolizumab in Crohn's disease, sponsored by Leiden University Medical Center. Primary endpoints: Baseline immune and stromal cell status as predictor of response and Changes in cellular parameters associated with favorable response. Planned start Sep 2015; status: not yet recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON42625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42625.